All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Sobi secures FDA approval for Gamifant to treat MAS in Still’s disease
The FDA approval was based on pooled data from two studies, including a Phase 3 trial, in which 54% of patients achieved a complete response.
XtalPi, Pfizer expand collaboration to advance AI-driven drug discovery
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development.
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
Qilu Pharmaceutical is a vertically integrated pharmaceutical company in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).
Pfizer’s Hympavzi shows positive results in Phase 3 haemophilia study
The results from the Phase 3 BASIS study showed the superiority of once-weekly Hympavzi in improving bleeding outcomes compared to on-demand treatment.
Porton Advanced, EVA Pharma partner to expand CAR T-cell therapies
The partnership will focus on the development and large-scale production of lentiviral vectors, crucial for CAR T-cell therapies targeting cancers.
Gilead, Kymera partner to develop novel CDK2 degraders
The collaboration aims to advance the development of treatments for various cancers, including breast cancer and other solid tumours.
Bayer, THU expand collaboration to boost drug discovery in China
The expanded collaboration focuses on key therapeutic areas, including oncology, cardiovascular and renal diseases, neurology and rare diseases, and immunology.
Novoheart collaboration to develop mini-heart models for HLHS treatment
The collaboration aims to enhance understanding and treatment of HLHS, a severe congenital heart defect, by providing personalised insights into its causes and potential therapies.
Ovid Therapeutics sells ganaxolone royalties to Immedica Pharma
Ganaxolone is approved in the EU, Great Britain, the US, and China for epileptic seizures in patients aged two to 17 with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder.
PTC secures EC approval for Sephience to treat phenylketonuria
Sephience, which acts as a dual pharmacological chaperone to effectively reduce blood Phe levels, is indicated for treating hyperphenylalaninaemia (HPA) in patients with phenylketonuria (PKU).